title: Both low-dose arotinoid ethylester and acitretin are effective in the treatment of familial erythrokeratodermia variabilis.
abstract: We previously reported a large Chinese pedigree of erythrokeratodermia variabilis (EKV). A unique feature was that some of the affected members experienced transitory pustules on the border of classic lesions. Here we prescribed oral arotinoid ethylester and acitretin to two of the affected members in the pedigree, at starting dosage of 0.03 mg/day for arotinoid ethylester and 30 mg/day for acitretin, maintenance dosage of 0.03 mg every other day and 20 mg/day, respectively. Both patients reached complete clearance of the lesions during the treatment period. Side effect was negligible for the case on arotinoid ethylester. The patient on acitretin experienced elevated level of serum triglyceride and alanine aminotransferase that restrained further use.
authors.affiliation: Department of Dermatology, No.1 Hospital of China Medical University, Shenyang, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Yuxiao
authors.initials: Y
authors.lastname: Hong
authors.forename: Song
authors.initials: S
authors.lastname: Zheng
authors.forename: Wei
authors.initials: W
authors.lastname: Huo
authors.forename: Ruiqun
authors.initials: R
authors.lastname: Qi
authors.forename: Long
authors.initials: L
authors.lastname: Geng
authors.forename: Hong-Duo
authors.initials: HD
authors.lastname: Chen
authors.forename: Xing-Hua
authors.initials: XH
authors.lastname: Gao
mesh_terms: D017255:Acitretin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols; D044466:Asian People; D001565:Benzoates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide; D004317:Doxorubicin; D056266:Erythrokeratodermia Variabilis / Q000188:drug therapy* / Q000473:pathology; D005047:Etoposide; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D011241:Prednisone; D012176:Retinoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D014750:Vincristine; D055815:Young Adult
chemical_list: D001565:Benzoates; D007641:Keratolytic Agents; D012176:Retinoids; D014280:Triglycerides; D014750:Vincristine; D005047:Etoposide; C034814:ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid; D004317:Doxorubicin; D003520:Cyclophosphamide; D000410:Alanine Transaminase; D017255:Acitretin; D011241:Prednisone
keywords: acitretin; arotinoid ethylester; familial erythrokeratodermia variabilis; treatment